Spatial profiling reveals complex cellular responses of anti-IL5 treatment with mepolizumab in eosinophilic chronic rhinosinusitis with nasal polyposis A broad biological impact of anti-IL5 therapy in eosinophilic CRSwNP that includes altering the expression of cellular canonical type 2 pathways and non–ty

The April 2026 Issue of #JLB starts with "#SpatialProfiling reveals complex cellular responses of anti-IL5 treatment with #Mepolizumab in eosinophilic chronic #Rhinosinusitis with nasal polyposis" by Nicholas West and colleagues @griffith.edu.au

MHRA approves Nucala for eosinophilic COPD in adults on triple therapy - PharmaTimes New biologic option shown to reduce exacerbations and extend time to first flare

#MHRA #GSK #Nucala #mepolizumab #eosinophilicCOPD #tripletherapy #biologics #UK #addonmaintenancetreatment #uncontrolledCOPD #MATINEE #METREX #KingsCentreforLungHealth #RespiratoryMedicine #COPDpatients #NICE #emergencyhospitaladmissions #COPDExacerbations #SMC #reimbursement
zurl.co/ro5Og

GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

#GSK #depemokimab #severeasthma #Exdensur #CRSwNP #respiratory #immunology #inflammation #Nucala #mepolizumab #COPD #rarediseases #SerumLifeScienceEurope #Anktiva #NMIBC #SFLPharma #Aumseqa #NSCLC #Cytokinetics #Myqorzo #hypertrophiccardiomyopathy #Moderna #Mnexspike #COVID19vaccine
zurl.co/l8WfN

Potential Role of Mepolizumab Therapy in Formation of NETs, EETs in EGPA Patients with EGPA receiving mepolizumab for 6 months saw an impact on neutrophil extracellular trap and eosinophilic extracellular trap formation.

#ACR25: In patients with the #EGPA type of #ANCA-associated vasculitis (#AAV) who receive #Mepolizumab treatment for 6 months, an impact on the formation of #NETs and #EETs has been observed.

Read more: https://bit.ly/4oLOO97

#RareDisease #Rheumatology #RheumSky #MedSky

An Uncommon Case of Non-Specific Interstitial Pneumonia (#NSIP) Associated With Idiopathic Hypereosinophilic Syndrome (#HES) Reversed by #Mepolizumab
onlinelibrary.wiley.com/doi/10.1002/...

Canonica (Humanitas): "Nuovi dati confermano efficacia anti Il-5 in asma grave" (Adnkronos) - I primi risultati dello studio Realiti-A, "osservazionale prospettico, quindi di notevole qualità", sulla capacità di mepolizumab, inibitore di IL-5, di ridurre in modo significativo le riacutizzazioni di malattia asmati...

Canonica (Humanitas): "Nuovi dati confermano efficacia anti Il-5 in asma grave" ... LEGGI TUTTO #Asma #Salute #RicercaMedica #Mepolizumab #IL5

Relapse of Eosinophilic Granulomatosis With Polyangiitis (#EGPA) Despite Maintenance Treatment With Low-Dose #Mepolizumab
onlinelibrary.wiley.com/doi/10.1002/...

🎉A decade of Nucala🎉 - and an inspiring symposium to match!

Grateful to be part of the amazing speaker lineup and the ongoing conversation around eosinophilic airway disease and its future.

Cheers to 10 years of progress!

#Nucala #Mepolizumab #Immunology #ImmunoSky #MedSky #CRS #Eosinophil

Allergic Bronchopulmonary #Mycosis Caused by #Schizophyllum commune Successfully Treated With #Mepolizumab

Happy to start 2025 with our new article in JACI! www.jacionline.org/article/S009...
So Mepo is definitely worth a shot for L-HES patients (especially as it’s the only reimbursed biologic for HES at the moment), but we should also explore other dosing regimens and treatments. #LHES #Mepolizumab

Just used this article to decide to start someone on #mepolizumab- great asthma resource for #pulmCC http://bit.ly/presciseasthma @IUPCCM